Hibah Awwad, Ph.D.

Clinical Assistant Professor

Department of Pharmaceutical Sciences

Phone (405) 271-6593 x47210

Fax (405) 271-7505

Office CPB 315

Email hawwad@ouhsc.edu


Summary

Traumatic brain injury (TBI) is a leading cause of death and disability in young adults. To date, there are no FDA-approved drugs for TBI. The main focus of our research is to study the mechanisms of neurotoxic factors released after a brain injury, in order to identify potential targets for novel neuroprotective therapies. Scientific methods include neuropharmacology via molecular, biochemical, behavioral and imaging techniques.



Education & Experience

Ph.D. in Pharmacology

University of Houston, Houston, TX

2005

B.Sc. in Pharmacy

Amman University, Amman, Jordan

1998

Certificate in Preparing Future Faculty

University of Oklahoma Health Sciences Center, Oklahoma City, OK

2010


Honors & Awards

Professional Awards

Provost's Teaching Award for Early Career Faculty

University of Oklahoma Health Sciences Center, OKC, OK

Educator of the Year Award

University of Oklahoma College of Pharmacy

AACP WalMart Scholar

American Association of Colleges of Pharmacy (San Antonio general meeting)



Academic Awards

Postdoctoral Travel Award

Society for Neuroscience (Washington, DC)

2011

Postdoctoral Research Award (for scientific achievement - travel award)

Graduate College; University of Oklahoma Health Sciences Center, OKC, OK

2010

Postdoctoral Scientific Research Award - Neuropharmacology Division

ASPET. Experimental Biology/Federation of American Societies. Experimental Biology (Anaheim, CA)

2010

John B. Bruce Scholarship Award - Outstanding postdoctoral fellow in pharmaceutical Sciences

OU College of Pharmacy, Oklahoma City, OK

2010


Publications & Presentations

1 2 3 4 > >>
  1. Baier M P, Falcon E C, Moehlenbrock C W, Edwards A C, Lerner M R, Awwad H O. Elevated cerebrospinal histamine levels following traumatic brain injury in rats. 2018
  2. Falcon E C, Baier M P, Oleru A, Moehlenbrock C W, Lerner M R, Awwad H O. Region specific elevation of histamine-3 receptor in traumatic brain injury. 2018
  3. Baier M P, Lerner M R, Awwad H O. Histamine Release in Traumatic Brain Injury: Neurotoxic or Neuroprotective. American Journal of Pharmaceutical Education. 2018; 82 : 555
  4. Awwad H O, Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M R, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural brain research. 2018
  5. Baier M, Lerner M R, Awwad H O. Temporal changes in mast cell release following a mild traumatic brain injury in rats. Society for Neuroscience Annual Meeting Proceedings. 2017
1 2 3 4 > >>



Grants

1 2 >>
  • Pharmacotherapy of Traumatic Brain Injury Accompanied by Hemorrhagic Shock. 2017.
  • Histamine release in Traumatic Brain Injury: neurotoxic or neuroprotective?. 2017.
  • Unveiling neurotoxic mechanisms in a traumatic brain injury model. 2015.
  • Molecular mechanisms of chronic pain and its modulation by posttraumatic stress disorder and Nociceptin/Orphanin FQ. 2011.
  • Nociceptin/Orphanin FQ peptide (NOP) receptor antagonists for treatment of TBI-induced co-morbid chronic pain. 2014.
1 2 >>